FDA Grants Can-Fite IND Clearance for a Phase IIb Study
DENVER, Colo., May 09, 2024 (247marketnews.com)- Can-Fite BioPharma Ltd. (NYSE:CANF) stated that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for Namodenoson, for the Company’s ongoing Phase IIb clinical study.
“The IND activation for the treatment of MASH patients with Namodenoson, opens the gate for the enrolment of US based patients and will contribute to the heterogeneity of the population of this study,” commented Can-Fite’s CEO, Motti Farbstein. ” As we are already enrolling patients for this study, we hope that in the next few months, we will complete recruitment. We are committed to improve the lives of MASH patients and based on the efficacy of the drug in the Phase IIa study, we are proud to develop a new potential treatment to address this disease.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (CANF)
- OceanaGold Reports Record Quarterly Net Profit
- OceanaGold Announces Effective Date of Share Consolidation in Connection with Proposed U.S. Listing
- OceanaGold Reports Voting Results from its 2025 Annual General and Special Meeting
- OceanaGold Reports First Quarter 2025 Operating & Financial Results
- MoBot alert highlights: NYSE: FINV, NASDAQ: ATER, NASDAQ: IRD, NASDAQ: DVLT, NYSE: CANF (03/18/25 07:00 PM)